Simon Bailey

Physiochemical drug properties associated with in vivo toxicological outcomes

Jason D. Hughes, Julian Blagg, David A. Price et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 973 citations

Pharmacy, Pharmacology, Toxicology +14

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

Paul A. Northcott, David Shih, John Peacock et al. · Nature · 2012 · 921 citations · Full text

Medicine, Genetics, Oncology +17

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups

David W. Ellison, James Dalton, Mehmet Koçak et al. · Acta Neuropathologica · 2011 · 557 citations

Veterinary Medicine, Cancer Biology, Oncology +13

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study

Ed C. Schwalbe, Janet C. Lindsey, Sirintra Nakjang et al. · The Lancet Oncology · 2017 · 515 citations · Full text

Medicine, Oncology, Pediatrics +17